Silk Road Medical Inc. (SILK) Tops Q4 EPS by 9c, provides guidance

Silk Road Medical Inc. (NASDAQ: SILK) reported Q4 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $47.27 million versus the consensus estimate of $41.93 million.

GUIDANCE:

Silk Road Medical Inc. sees FY2024 revenue of $194-198 million, versus the consensus of $191.4 million.

For earnings history and earnings-related data on Silk Road Medical Inc. (SILK) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c